Today in Business
SEE OTHER BRANDS

Your business news from the world

CISL Seoul Announces Launch of Dermatologist-Developed K-Clinical Skincare Line

CISL Seoul clinical skincare products including Dual Infushot Serum, Biobarrier Capsule Cream, and Ultra Wrinkle Correxion Serum inspired by Korean dermatology.

CISL Seoul introduces K-Clinical Skincare — dermatologist-developed formulas inspired by Korea’s medical innovation.

Born in Seoul’s dermatology clinics, CISL Seoul delivers clinical results at home with dermatologist-developed formulas.

CISL Seoul is not K-Beauty. It’s K-Clinical — inspired by dermatology, designed for real results.”
— Lee Young Woo, Founder & CEO of CISL Seoul
SEOUL, SEOUL, SOUTH KOREA, October 2, 2025 /EINPresswire.com/ -- CISL Seoul today announced the launch of its new clinical skincare line, introducing a new category the brand calls K-Clinical. Developed by expert dermatologists in South Korea, the global capital of dermatology and medical innovation, CISL Seoul transforms cutting-edge procedures into skincare routines designed for daily use.

K-Clinical: beyond K-Beauty

Unlike conventional K-Beauty brands, CISL Seoul positions itself as K-Clinical: evidence-based skincare co-developed with dermatologists to achieve results once only possible in professional settings.

The brand’s portfolio is built around two complementary pillars:

Procedure-inspired care: Translating in-clinic treatments into skincare formulas. The flagship CISL DUAL INFUSHOT™ Skinbooster Serum is modeled after Korea’s renowned “salmon injection” procedure, celebrated for its regenerative effects. Its dual-chamber design combines two potent formulas fresh at every pump, replicating the precision of advanced treatments at home.

Post-care support: Focusing on recovery and resilience. The CISL BIOBARRIER™ Recovery Capsule Cream calms sensitivity and strengthens the skin barrier, while the CISL ULTRA WRINKLE CORREXION™ Serum improves firmness and elasticity, extending the benefits of professional procedures into everyday routines.

From patient to CEO

CISL Seoul’s origins lie in a personal story. Its founder, once a patient seeking clinical skincare solutions, identified a gap: advanced results were accessible only inside Seoul’s elite clinics. Partnering with his trusted dermatologists, he transitioned from patient to CEO, creating a brand that makes Korean clinical expertise available worldwide.

Innovation and ingredients

CISL Seoul’s formulas are powered by proven dermatological science. Ingredients include PDRN (salmon DNA), known in Korean dermatology for its regenerative properties, Matrixyl 3000 peptides for wrinkle reduction, and dermatologist-recommended concentrations of retinol. Together, they deliver visible improvements in hydration, barrier repair, firmness, and overall skin health.

A new standard in skincare

“CISL Seoul is not K-Beauty. It is K-Clinical — inspired by dermatology, designed for real results,” said Lee Young Woo, Founder & CEO of CISL Seoul.

Every product is co-developed with dermatologists, merging clinical expertise with minimalist design and uncompromising safety. CISL Seoul represents more than another brand launch — it is the bridge between luxury clinical procedures and daily skincare.

About CISL Seoul

CISL Seoul is a clinical skincare brand born in Seoul’s dermatology clinics. Co-developed with expert dermatologists, CISL introduces K-Clinical skincare — bridging medical innovation and everyday routines.

For more information, visit www.cislseoul.com

Nuria Crespi Rosell
CISL Seoul
+82 10-7245-9335
email us here
Visit us on social media:
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions